HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Fluvoxamine for phobia of storms.

AbstractSpecific phobias are not usually treated unless they are disabling. Behavioural therapy is the treatment of choice for disabling specific phobias. Pharmacotherapy is generally not considered to be effective in specific phobias, and is therefore not used for this indication. However, selective serotonin reuptake inhibitors have been reported to be effective in various anxiety disorders, and may be effective in specific phobias as well. This case report describes the successful treatment of phobia of storms with fluvoxamine in an 11-year-old boy. Fluvoxamine and other selective serotonin reuptake inhibitors may be a suitable option for treatment of disabling cases of specific phobia when behavioural therapy is not feasible for various reasons.
AuthorsR Balon (Affiliation: Department of Psychiatry and Behavioral Neurosciences, Wayne State University School of Medicine, Detroit, Michigan, USA.)
JournalActa psychiatrica Scandinavica (Acta Psychiatr Scand) Vol. 100 Issue 3 Pg. 244-5; discussion 245-6 (Sep 1999) ISSN: 0001-690X [Print] DENMARK
PMID10493092 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Anti-Anxiety Agents
  • Serotonin Uptake Inhibitors
  • Fluvoxamine
Topics
  • Anti-Anxiety Agents (therapeutic use)
  • Child
  • Fear
  • Fluvoxamine (therapeutic use)
  • Humans
  • Male
  • Phobic Disorders (drug therapy)
  • Serotonin Uptake Inhibitors (therapeutic use)
  • Treatment Outcome
  • Weather

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD